Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.

Inclusion Criteria:

• Eligible healthy donors will be at least 18 years of age.

Exclusion Criteria:

• Healthy donors younger than 18 years of age

• This study will access data and specimens from patients who consented to specimen banks (approximately 3262 patients) There is a waiver of consent for this study regarding patient data banked under the tissue banks.
• Healthy donors will be consented prior to sample acquisition (approximately 100 patients)

All of the individual participant data collected during the trial, after deidentification will be available for sharing with other researchers.